PubRank

N P Nair

Author PubWeight™ 74.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nat Neurosci 1998 4.76
2 Circadian rhythms of melatonin and cortisol in aging. Biol Psychiatry 1989 2.41
3 Basal cortisol levels and cognitive deficits in human aging. J Neurosci 1994 1.97
4 Stress-induced declarative memory impairment in healthy elderly subjects: relationship to cortisol reactivity. J Clin Endocrinol Metab 1997 1.56
5 Increased cortisol levels and impaired cognition in human aging: implication for depression and dementia in later life. Rev Neurosci 1999 1.47
6 Factors in the development of severe forms of tardive dyskinesia. Am J Psychiatry 1990 1.39
7 Longitudinal study of basal cortisol levels in healthy elderly subjects: evidence for subgroups. Neurobiol Aging 1996 1.07
8 A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial. Acta Psychiatr Scand Suppl 1990 1.05
9 Late-onset bipolar disorder. Psychiatr Clin North Am 1988 0.99
10 Individual differences in hypothalamic-pituitary-adrenal activity in later life and hippocampal aging. Exp Gerontol 1995 0.97
11 Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer's disease. Neuroscience 1986 0.94
12 Apomorphine-induced penile tumescence in impotent patients--preliminary findings. Prog Neuropsychopharmacol Biol Psychiatry 1987 0.94
13 A five-year outcome of discharged chronic psychiatric patients. Can Psychiatr Assoc J 1972 0.94
14 Apomorphine: clinical studies on erectile impotence and yawning. Prog Neuropsychopharmacol Biol Psychiatry 1989 0.94
15 Diazepam in high doses is effective in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1982 0.93
16 Circadian rhythm of plasma melatonin in endogenous depression. Prog Neuropsychopharmacol Biol Psychiatry 1984 0.89
17 Alzheimer's disease may not be a spirochetosis. Neuroreport 1999 0.89
18 Differential effect of unilateral and bilateral ECT. Am J Psychiatry 1970 0.88
19 The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. J Clin Pharmacol 1987 0.87
20 Reduced lumbar CSF somatostatin levels in Alzheimer's disease. Life Sci 1982 0.87
21 Effect of sleep deprivation on dopamine receptor function in normal subjects. J Neural Transm 1981 0.86
22 Studies of a neurochemical link between depression, anxiety, and stress from [3H]imipramine and [3H]paroxetine binding on human platelets. Biol Psychiatry 1994 0.86
23 The Major Depression Rating Scale (MDS). Inter-rater reliability and validity across different settings in randomized moclobemide trials. Danish University Antidepressant Group. J Affect Disord 1997 0.84
24 Comparative potencies of calcium channel antagonists and antischizophrenic drugs on central and peripheral calcium channel binding sites. J Pharm Pharmacol 1985 0.83
25 Effect of sulpiride, an atypical neuroleptic, on apomorphine-induced growth hormone secretion. Brain Res Bull 1982 0.81
26 High doses of diazepam improve neuroleptic-resistant chronic schizophrenic patients. Psychopharmacology (Berl) 1983 0.81
27 Clinical and neuroendocrine studies with cholecystokinin peptides. Ann N Y Acad Sci 1985 0.80
28 The Kleine-Levine syndrome--a variant? J Clin Psychiatry 1978 0.80
29 A post-mortem comparison of the cortical cholinergic system in Alzheimer's disease and Pick's disease. J Neurol Sci 1983 0.80
30 Baclofen in the treatment of tardive dyskinesia. Am J Psychiatry 1978 0.80
31 Outcome variables in presymptomatic individuals at higher risk of developing Alzheimer disease. Alzheimer Dis Assoc Disord 1996 0.80
32 Glucocorticoid receptor gene expression is unaltered in hippocampal neurons in Alzheimer's disease. Brain Res Mol Brain Res 1993 0.79
33 Increase in the content of quinolinic acid in cerebrospinal fluid and frontal cortex of patients with hepatic failure. J Neurochem 1986 0.79
34 CSF acetylcholinesterase in dementia and in sequential samples of lumbar CSF. Neurobiol Aging 1984 0.79
35 Effect of lithium on hypothalamic-pituitary dopaminergic function. Acta Psychiatr Scand 1978 0.79
36 Levomepromazine receptor binding profile in human brain--implications for treatment-resistant schizophrenia. Acta Psychiatr Scand 1993 0.78
37 Parkinsonism induced by high doses of diazepam. Biol Psychiatry 1985 0.78
38 Plasma melatonin--an index of brain aging in humans? Biol Psychiatry 1986 0.78
39 Lack of cholinergic deficit in the neocortex in Pick's disease. Prog Neuropsychopharmacol Biol Psychiatry 1983 0.78
40 A 10-year follow-up study of tardive dyskinesia. Acta Psychiatr Scand 1992 0.78
41 Clinical relevance of serum nortriptyline and 10-hydroxy-nortriptyline measurements in the depressed elderly: a multicenter pharmacokinetic and pharmacodynamic study. Neuropsychopharmacology 1996 0.78
42 The effect of Yohimbine, an alpha2 adrenergic receptor antagonist, on the growth hormone response to apomorphine in normal subjects. J Psychiatry Neurosci 1996 0.77
43 Cholecystokinin appears to have antipsychotic properties. Prog Neuropsychopharmacol Biol Psychiatry 1982 0.77
44 Is levomepromazine a useful drug in treatment-resistant schizophrenia? Acta Psychiatr Scand 1992 0.77
45 A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression. J Affect Disord 1994 0.77
46 Effect of some peptides on dopaminergic function in man. J Neural Transm Suppl 1990 0.77
47 Buspirone: a potential atypical neuroleptic. Life Sci 1983 0.77
48 Platelet 3H-imipramine binding and red blood cell choline in affective disorders: indications of heterogeneous pathogenesis. Biol Psychiatry 1983 0.77
49 Normalization of platelet [3H]imipramine binding in depressed patients during remission. Eur J Pharmacol 1982 0.77
50 Effect of normal aging on the prolactin response to graded doses of sulpiride and to arginine. Prog Neuropsychopharmacol Biol Psychiatry 1985 0.77
51 Effect of domperidone on apomorphine-induced growth hormone secretion in normal men. J Neural Transm 1982 0.77
52 beta-Endorphin and naloxone in psychiatric patients: clinical and biological effects. Am J Psychiatry 1979 0.77
53 Comparative autoradiographic distribution of calcium channel antagonist binding sites for 1,4-dihydropyridine and phenylalkylamine in rat, guinea pig and human brain. Prog Neuropsychopharmacol Biol Psychiatry 1985 0.77
54 Stereospecificity of the dopamine receptor mediating the growth hormone response to apomorphine in man. Short communication. J Neural Transm Gen Sect 1991 0.77
55 Cholecystokinin and schizophrenia. Prog Brain Res 1986 0.77
56 Neurotransmitter and receptor deficits in senile dementia of the Alzheimer type. Can J Neurol Sci 1986 0.77
57 Neuroendocrine evaluation of CCK-peptides on dopaminergic function in man. Prog Neuropsychopharmacol Biol Psychiatry 1983 0.77
58 Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy. J Neurol Neurosurg Psychiatry 1976 0.77
59 Clonidine-induced growth hormone secretion in chronic schizophrenia. Acta Psychiatr Scand 1983 0.77
60 Effect of imipramine on the circadian rhythm of plasma melatonin in unipolar depression. Chronobiol Int 1986 0.76
61 Cardiovascular, neuroendocrine, and monoaminergic responses to psychological stressors: possible differences between remitted panic disorder patients and healthy controls. Biol Psychiatry 1996 0.76
62 Localization of cholecystokinin binding sites in canine brain using quantitative autoradiography. Prog Neuropsychopharmacol Biol Psychiatry 1991 0.76
63 Cholecystokinin peptides, dopamine and schizophrenia--a review. Prog Neuropsychopharmacol Biol Psychiatry 1985 0.76
64 Characterization and possible role of growth factor and lymphokine receptors in the regulation of cholinergic function in the mammalian brain. Prog Clin Biol Res 1989 0.76
65 Treatment of Alzheimer's disease with sabeluzole: functional and structural correlates. Clin Neuropharmacol 1997 0.76
66 The dexamethasone suppression test and treatment outcome in elderly depressed patients participating in a placebo-controlled multicenter trial involving moclobemide and nortriptyline. Biol Psychiatry 1997 0.76
67 Unique [3H]tryptamine binding sites in rat brain: distribution and pharmacology. Arch Int Pharmacodyn Ther 1984 0.76
68 A double blind comparison of alprazolam and amitriptyline hydrochloride in the treatment of nonpsychotic depression. Can J Psychiatry 1988 0.76
69 Nucleus basalis neuronal loss and neuritic plaques in advanced Alzheimer's disease. Can J Physiol Pharmacol 1986 0.76
70 Verapamil in the treatment of chronic schizophrenia. Psychopharmacol Bull 1987 0.76
71 Antagonists of excitatory amino acids and cyclic guanosine monophosphate in cerebellum. Neuropharmacology 1982 0.76
72 Effect of hydrocortisone on basal and apomorphine-induced growth hormone secretion in normal subjects. Clin Invest Med 1988 0.76
73 Imipramine treatment differentially affects platelet 3H-imipramine binding and serotonin uptake in depressed patients. Life Sci 1985 0.76
74 Platelet 3H-imipramine binding distinguishes depression from Alzheimer dementia. Life Sci 1985 0.76
75 Lack of association between [3H]imipramine binding sites and uptake of serotonin in control, depressed and schizophrenic patients. Neuropharmacology 1983 0.76
76 Differential actions of classical and atypical neuroleptics on mouse nigrostriatal neurons. Prog Neuropsychopharmacol Biol Psychiatry 1983 0.76
77 An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study. J Psychiatry Neurosci 1995 0.76
78 Effect of clozapine on apomorphine-induced growth hormone secretion and serum prolactin concentrations in schizophrenia. Neuropsychobiology 1979 0.75
79 Platelet imipramine binding in patients with panic disorder and major familial depression. J Psychiatr Res 1987 0.75
80 Dopamine and schizophrenia. A reappraisal in the light of clinical studies with clozapine. Can Psychiatr Assoc J 1977 0.75
81 Efficacy and safety of brofaromine in depression: a Canadian multicenter placebo controlled trial and a review of comparative controlled studies. Clin Neuropharmacol 1992 0.75
82 Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies. Clin Neuropharmacol 1993 0.75
83 Serotonin uptake in panic disorder and agoraphobia. Neuropsychopharmacology 1988 0.75
84 Differences in symptomatology and diagnostic profile in younger and elderly depressed inpatients. J Affect Disord 2001 0.75
85 Visualization of growth factor receptor sites in rat forebrain. Synapse 1988 0.75
86 Loxapine succinate in the treatment of chronic schizophrenia. Curr Ther Res Clin Exp 1976 0.75
87 Circadian rhythms and psychiatry. Br J Psychiatry 1984 0.75
88 Effect of apomorphine on melatonin secretion in normal subjects. Prog Neuropsychopharmacol Biol Psychiatry 1987 0.75
89 Effect of sleep deprivation on the growth hormone response to the alpha-3 adrenergic receptor agonist, clonidine, in normal subjects. J Neural Transm (Vienna) 1997 0.75
90 Hypothalamic-pituitary dopaminergic function in hepatic failure in man. J Neural Transm 1982 0.75
91 Effect of sodium valproate and baclofen in tardive dyskinesia: clinical and neuroendocrine studies. Adv Biochem Psychopharmacol 1980 0.75
92 Effect of CCK-33 on prolactin and apomorphine-induced growth hormone secretion in man. Horm Metab Res 1983 0.75
93 Differential changes in regional brain ganglioside and neutral glycosphingolipid contents in Alzheimer's disease. Adv Exp Med Biol 1995 0.75
94 Proceedings: Penfluridol in the treatment of schizophrenia: clinical and psychometric findings. Psychopharmacol Bull 1976 0.75
95 Effect of choline on central dopaminergic function in normal subjects. J Neural Transm 1981 0.75
96 The effect of methyltestosterone on the growth hormone response to the dopamine receptor agonist, apomorphine. Prog Neuropsychopharmacol Biol Psychiatry 1991 0.75
97 Transmembrane lithium distribution and hypertension in manic depressive patients. Prog Neuropsychopharmacol Biol Psychiatry 1989 0.75
98 Pimozide: EEG effects related to clinical response. Can Psychiatr Assoc J 1971 0.75
99 The effect of tardive dyskinesia on body weight. Acta Psychiatr Scand 1987 0.75
100 Evidence for involvement of dopamine in the action of diazepam: potentiation of haloperidol and chlorpromazine action in the brain. Adv Biochem Psychopharmacol 1980 0.75
101 Trazodone in the treatment of schizophrenias. Curr Ther Res Clin Exp 1973 0.75
102 [Comparison of the hypnotic activity of triazolam and flurazepam]. Union Med Can 1979 0.75
103 Plasma beta-endorphin levels in chronic schizophrenic patients normal controls. Artif Organs 1979 0.75
104 Comprehensive clinical studies with trazodone. Curr Ther Res Clin Exp 1973 0.75
105 Neurochemical and receptor theories of depression. Psychiatr J Univ Ott 1989 0.75
106 Trazodone in the treatment of organic brain syndromes, with special reference to psychogeriatrics. Curr Ther Res Clin Exp 1973 0.75
107 CCK-8 antagonizes apomorphine-induced growth hormone secretion in normal subjects. Horm Metab Res 1986 0.75
108 Effect of lithium and neuroleptic combination on lithium transport, blood pressure, and weight in bipolar patients. Biol Psychiatry 1989 0.75
109 CCK-33 antagonizes apomorphine-induced growth hormone secretion and increases basal prolactin levels in man. Neuropeptides 1984 0.75
110 Bromocriptine: effect on serum prolactin and growth hormone in psychogeriatric hospital patients. J Am Geriatr Soc 1978 0.75
111 Reduced cortical choline acetyltransferase activity in Gerstmann-Sträussler syndrome. Prog Neuropsychopharmacol Biol Psychiatry 1982 0.75
112 Psychogeriatric clinical, electro-encephalographic and autopsy findings. Neuropsychobiology 1997 0.75
113 Benzodiazepines and GABAergic regulation of nigrostriatal neurons: lack of tolerance. Prog Neuropsychopharmacol Biol Psychiatry 1984 0.75
114 Plasma magnesium in chronic schizophrenia. A preliminary report. Int Pharmacopsychiatry 1979 0.75
115 Gabaergic regulation of nigrostriatal neurons: coupling of benzodiazepine and GABA receptors. Prog Neuropsychopharmacol Biol Psychiatry 1982 0.75
116 Unchanged platelet 3H-imipramine binding in normal subjects after imipramine administration. Biol Psychiatry 1985 0.75
117 Coexistence of central and peripheral benzodiazepine binding sites in the human pineal gland. Life Sci 1987 0.75
118 The effect of electroconvulsive therapy on endorphins in depression. Biol Psychiatry 1988 0.75
119 Effect of naloxone or levallorphan on serum prolactin concentrations and apomorphine-induced growth hormone secretion. Acta Psychiatr Scand 1979 0.75
120 Altered platelet 3H-imipramine binding in schizo-affective and depressive disorders. Biol Psychiatry 1983 0.75
121 Growth hormone response to apomorphine, a dopamine receptor agonist, in normal aging and in dementia of the Alzheimer type. Neurobiol Aging 1989 0.75
122 Care of chronic psychotics. Br Med J 1971 0.75
123 Cholecystokinin-octapeptide in chronic schizophrenia: a double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 1984 0.75
124 GABAergic and opioid regulation of the substantia nigra innominata-cortical cholinergic pathway in the rat. Prog Neuropsychopharmacol Biol Psychiatry 1984 0.75
125 Drug-induced growth hormone and prolactin responses in schizophrenia research. Prog Neuropsychopharmacol Biol Psychiatry 1982 0.75
126 Striatal 3-methoxytyramine as an index of dopamine release effects of electrical stimulation. Neurosci Lett 1982 0.75
127 Verapamil in refractory schizophrenia: a case report. Prog Neuropsychopharmacol Biol Psychiatry 1987 0.75
128 Effect of ascorbic acid on brain amphetamine concentrations in the rat. Prog Neuropsychopharmacol Biol Psychiatry 1987 0.75
129 Platelet 3H-imipramine binding: a state-dependent marker in depression. Prog Neuropsychopharmacol Biol Psychiatry 1984 0.75
130 Muscarinic, benzodiazepine, GABA, chloride channel and other binding sites in frontal cortex in hepatic coma in man. Prog Neuropsychopharmacol Biol Psychiatry 1987 0.75
131 Differential effects of trazodone in depressed, schizophrenic and geriatric patients. Int J Clin Pharmacol 1974 0.75
132 Red cell choline in Korsakoff psychosis. Prog Neuropsychopharmacol Biol Psychiatry 1985 0.75